Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05698888 Terminated - Multiple Myeloma Clinical Trials

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Start date: November 29, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

NCT ID: NCT05611853 Terminated - Clinical trials for Mantle Cell Lymphoma

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: November 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 trial to study the safety, pharmacokinetics and preliminary efficacy of BN301 given intravenously every 3 weeks.

NCT ID: NCT05354362 Terminated - Clinical trials for Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

MATCH
Start date: March 2, 2022
Phase: Phase 1
Study type: Interventional

This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

NCT ID: NCT05328102 Terminated - Clinical trials for Diffuse Large-cell B-cell Lymphoma

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Start date: April 15, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.

NCT ID: NCT05319028 Terminated - Clinical trials for Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start date: June 23, 2022
Phase: Phase 2
Study type: Interventional

Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.

NCT ID: NCT05296525 Terminated - Clinical trials for Non-Hodgkin Lymphoma

Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Start date: July 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved NK cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL).

NCT ID: NCT05244070 Terminated - Lymphoma Clinical Trials

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: September 14, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).

NCT ID: NCT05242146 Terminated - CNS Lymphoma Clinical Trials

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

STAR CNS
Start date: May 24, 2022
Phase: Phase 1
Study type: Interventional

The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.

NCT ID: NCT05222269 Terminated - CNS Lymphoma Clinical Trials

[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

Start date: October 5, 2022
Phase: Phase 2
Study type: Interventional

This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of [68Ga]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL) patients scheduled to undergo induction chemotherapy.

NCT ID: NCT05221385 Terminated - Solid Tumor Clinical Trials

Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma

Start date: April 12, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.